Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;188(6):e101-e105.
doi: 10.1111/bjh.16388. Epub 2020 Feb 22.

Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia

Fiorina Giona  1 , Francesco Malaspina  1 , Maria Caterina Putti  2 , Saverio Ladogana  3 , Rosamaria Mura  4 , Roberta Burnelli  5 , Nadia Vacca  6 , Lorenzo Rizzo  1 , Simona Bianchi  1 , Maria Luisa Moleti  1 , Anna Maria Testi  1 , Andrea Biondi  7 , Franco Locatelli  8 , Giuseppe Saglio  9 , Robin Foà  1
Affiliations

Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia

Fiorina Giona et al. Br J Haematol. 2020 Mar.
No abstract available

Keywords: chronic leukaemia; chronic myeloid leukaemia; imatinib; molecular studies; paediatric haematology; therapy.

PubMed Disclaimer

References

    1. Bansal, D., Shava, U., Varma, N., Trehan, A. & Marwaha, R.K. (2012) Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatric Blood & Cancer, 59, 481-484.
    1. Faber, E., Nausova, J., Jarosova, M., Egorin, M.J., Holzerova, M., Rozmanova, S., Maresova, I., Divoky, V. & Indrak, K. (2006) Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing. Leukaemia & Lymphoma, 47, 1082-1090.
    1. Giona, F., Mariani, S., Gnessi, L., Moleti, M.L., Rea, M., De Vellis, A., Marzella, D., Testi, A.M. & Foa, R. (2013) Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty. Haematologica, 98, e25-27.
    1. Giona, F., Putti, M.C., Micalizzi, C., Menna, G., Moleti, M.L., Santoro, N., Iaria, G., Ladogana, S., Burnelli, R., Consarino, C., Varotto, S., Tucci, F., Messina, C., Nanni, M., Diverio, D., Biondi, A., Pession, A., Locatelli, F., Piciocchi, A., Gottardi, E., Saglio, G. & Foa, R. (2015) Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. British Journal of Haematology, 170, 398-407.
    1. Gore, L., Kearns, P.R., de Martino, M.L., Lee, De Souza, C.A., Bertrand, Y., Hijiya, N., Stork, L.C., Chung, N.G., Cardos, R.C., Saikia, T., Fagioli, F., Seo, J.J., Landman-Parker, J., Lancaster, D., Place, A.E., Rabin, K.R., Sacchi, M., Swanink, R. & Zwaan, C.M. (2018) Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial. Journal of Clinical Oncology, 36, 1330-1338.

LinkOut - more resources